Exceptional Responders With Pancreatic Cancer to Chemotherapy

• Status: Enrolling by invitation
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an observational study enrolling patients with pancreatic cancer to identify genomic expression differences between exceptional responders and non-responders to standard of care chemotherapy. Data analysis of the gene expression profile of the exceptional responders compared to non-responders will define genomic patterns that may help understand their response to chemotherapy.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Adera Labs, LLC
• Collaborators: Hematology and Oncology Specialists; Maastricht University Medical Center; Memorial Sloan Kettering Cancer Center; The Pancreatic Cancer Treatment Center of Los Angeles; University of Nebraska; Weill Medical College of Cornell University

Criteria

Inclusion Criteria:

• Histological or cytological confirmation of pancreatic adenocarcinoma.

• Patient is treatment-naïve or currently receiving chemotherapy.

• ECOG performance status 0-2.

• Patients must have a hemoglobin of 7.5 g/dl or greater and be hemodynamically stable and/or physiologically compensated for their anemia.

Exclusion Criteria:

• HIV positive on antiretroviral therapy

• Pregnant or lactating

• Prior organ allograft

• Any medical or psychiatric condition that may interfere with the ability to comply with protocol treatment